evitria specializes in CHO-based transient expression of recombinant antibodies (including bispecific and fusion antibodies) for research purposes. evitria offers fast, cost-effective antibody expression with a flexible scale of production of purified antibody or supernatant according to client needs.
Headquartered in Zurich (Switzerland) and founded in 2010. evitria has since performed more than 55,000 transfections and produced more than 10,000 antibodies for its global customer base and excels with its benchmark-setting speed, reliability and quality.
In terms of antibody design evitria offers bispecific antibodies, fusion antibodies including Fc fusion proteins, antibody framework switching, Isotype switching, Glyco-engineering, ADCC modulation, chimerisation and humanization.
evitria has become one of the leading providers of custom-made recombinant antibodies and services for a broad range of clients from research institutions and start-ups to globally operating biotechnology and biopharmaceutical companies.